Innovent Biologics Inc
HKEX:1801
Innovent Biologics Inc
HKEX:1801
Price:
39.8 HKD
-0.62%
Market Closed
Updated:
May 20, 2024
Balance Sheet
Balance Sheet Decomposition
Innovent Biologics Inc
Innovent Biologics Inc
| Current Assets | 13.4B |
| Cash & Short-Term Investments | 18.8B |
| Receivables | 1B |
| Other Current Assets | -6.4B |
| Non-Current Assets | 7.2B |
| Long-Term Investments | 794.1m |
| PP&E | 4.9B |
| Intangibles | 1.3B |
| Other Non-Current Assets | 283.1m |
| Current Liabilities | 4.5B |
| Accounts Payable | 372.5m |
| Accrued Liabilities | 2.2B |
| Other Current Liabilities | 1.9B |
| Non-Current Liabilities | 3.6B |
| Long-Term Debt | 2.4B |
| Other Non-Current Liabilities | 1.2B |
Balance Sheet
Innovent Biologics Inc
Innovent Biologics Inc
Currency: CNY
| Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Cash & Cash Equivalents |
547
|
164
|
4 525
|
2 052
|
1 276
|
1 359
|
1 016
|
11 448
|
|
| Cash |
547
|
164
|
4 525
|
2 052
|
1 081
|
787
|
696
|
10 052
|
|
| Cash Equivalents |
0
|
0
|
0
|
0
|
196
|
573
|
320
|
1 396
|
|
| Short-Term Investments |
1 248
|
1 156
|
0
|
2 643
|
6 772
|
6 588
|
7 248
|
7 374
|
|
| Total Receivables |
14
|
13
|
21
|
250
|
475
|
968
|
575
|
1 006
|
|
| Accounts Receivables |
0
|
0
|
8
|
250
|
475
|
968
|
575
|
1 006
|
|
| Other Receivables |
14
|
13
|
14
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
37
|
58
|
66
|
359
|
706
|
1 347
|
1 429
|
968
|
|
| Other Current Assets |
25
|
55
|
74
|
152
|
238
|
1 288
|
1 238
|
1 334
|
|
| Total Current Assets |
1 871
|
1 446
|
4 686
|
5 455
|
9 467
|
11 551
|
11 507
|
13 428
|
|
| PP&E Net |
789
|
822
|
1 123
|
1 521
|
2 183
|
3 376
|
4 061
|
4 852
|
|
| PP&E Gross |
789
|
822
|
1 123
|
1 521
|
2 183
|
3 376
|
4 061
|
4 852
|
|
| Accumulated Depreciation |
57
|
117
|
178
|
252
|
353
|
517
|
761
|
1 036
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
33
|
772
|
1 198
|
1 270
|
|
| Note Receivable |
101
|
136
|
250
|
252
|
139
|
128
|
193
|
0
|
|
| Long-Term Investments |
0
|
0
|
0
|
2
|
13
|
417
|
630
|
794
|
|
| Other Long-Term Assets |
55
|
54
|
53
|
0
|
0
|
0
|
0
|
283
|
|
| Total Assets |
2 816
N/A
|
2 457
-13%
|
6 113
+149%
|
7 231
+18%
|
11 835
+64%
|
16 244
+37%
|
17 589
+8%
|
20 627
+17%
|
|
| Liabilities | |||||||||
| Accounts Payable |
21
|
35
|
43
|
84
|
121
|
195
|
326
|
373
|
|
| Accrued Liabilities |
31
|
106
|
533
|
784
|
820
|
1 678
|
1 517
|
2 156
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
5
|
10
|
33
|
271
|
387
|
914
|
1 220
|
|
| Other Current Liabilities |
24
|
17
|
84
|
143
|
274
|
790
|
742
|
728
|
|
| Total Current Liabilities |
76
|
163
|
670
|
1 044
|
1 486
|
3 050
|
3 499
|
4 477
|
|
| Long-Term Debt |
500
|
505
|
782
|
833
|
935
|
2 110
|
2 314
|
2 400
|
|
| Minority Interest |
426
|
320
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
3 198
|
3 411
|
466
|
598
|
634
|
754
|
1 046
|
1 223
|
|
| Total Liabilities |
4 200
N/A
|
4 400
+5%
|
1 918
-56%
|
2 474
+29%
|
3 055
+23%
|
5 913
+94%
|
6 859
+16%
|
8 100
+18%
|
|
| Equity | |||||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
1 395
|
1 997
|
7 557
|
9 129
|
9 762
|
12 045
|
13 836
|
14 672
|
|
| Additional Paid In Capital |
11
|
54
|
11 751
|
13 885
|
18 541
|
22 494
|
24 706
|
27 324
|
|
| Unrealized Security Profit/Loss |
0
|
0
|
0
|
0
|
0
|
120
|
121
|
105
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
2
|
18
|
20
|
|
| Total Equity |
1 384
N/A
|
1 943
-40%
|
4 194
N/A
|
4 756
+13%
|
8 780
+85%
|
10 330
+18%
|
10 730
+4%
|
12 528
+17%
|
|
| Total Liabilities & Equity |
2 816
N/A
|
2 457
-13%
|
6 113
+149%
|
7 231
+18%
|
11 835
+64%
|
16 244
+37%
|
17 589
+8%
|
20 627
+17%
|
|
| Shares Outstanding | |||||||||
| Common Shares Outstanding |
882
|
882
|
1 154
|
1 263
|
1 403
|
1 462
|
1 534
|
1 622
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
